Ravi Srinivasan

Nov 28, 2023 | lexology.com | James Egleton |Ravi Srinivasan

The EPO’s Enlarged Board of Appeal has recently made a key ruling on the issue of priority entitlement in decision G1/22 and G2/22. The decision represents a significant relaxation of the formal requirements that were previously been imposed on applicants and patentees to demonstrate the validity of a priority claim. It will be welcome news to rights holders.

Nov 1, 2023 | mondaq.com | Ravi Srinivasan |James Egleton

The recent Enlarged Board of Appeal decisions G1/22 and G2/22 on priority entitlement provide a good opportunity to review this complex issue. Join us for a review of priority entitlement at the EPO. We will cover: An outline of G1/22 and G2/22 and consideration of what that means for assessing whether a new applicant is a "successor in title" of the applicant for the priority application.

Oct 13, 2023 | mondaq.com | Chris Milton |Mark Roberts |Ravi Srinivasan

Article 53(c) EPC specifies a number of exceptions to patentability in the field of medicine, including "methods for the treatment of the human or animal body by surgery". These exceptions to patentability were included in the EPC on socio-ethical and public health grounds to ensure that medical and veterinary practitioners remain free to take any action necessary to treat or diagnose illnesses.

Sep 14, 2023 | mondaq.com | Graham Lewis |Chris Milton |Ravi Srinivasan

In order to place a new medicinal product on the market in Europe, it is necessary first to obtain a marketing authorisation. Most applications for marketing authorisations are made through a centralised procedure with the European Medicines Agency (EMA) which effectively leads to authorisation in all EU/EEA member states1, although other routes are available.

Sep 14, 2023 | mondaq.com | Graham Lewis |Chris Milton |Ravi Srinivasan

This document is intended to provide a brief introduction to Supplementary Protection Certificates (SPCs) for medicinal products. For more detailed information, please see our full briefing on this topic. SPCs are intellectual property rights available for active ingredients of human and veterinary medicinal products requiring marketing authorisation.